Condition: Warm Autoimmune Hemolytic Anemia (WAIHA) · ITP - Immune Thrombocytopenia · Warm Autoimmune Hemolytic Anemia · Sponsor: CRISPR Therapeutics AG
This is a single-arm, open-label, multicenter, ascending dose Phase 1/2 trial evaluating the safety and preliminary efficacy of CTX112 or Zugocabtagene geleucel (zugo-cel) in adult participants with relapsed/refractory primary Immune Thrombocytopenia (ITP) and relapsed/refractory primary Warm Autoimmune Hemolytic Anemia (wAIHA).
This description comes directly from the study's public registry record.
Clinical Trials · 877-214-4634 · medicalaffairs@crisprtx.com
Always discuss trial participation with your own doctor first.
| Mayo Clinic in Rochester | Rochester, Minnesota, United States | Recruiting |
| University of Nebraska Medical Center | Omaha, Nebraska, United States | Recruiting |
| Universitaetsklinikum Koeln | Cologne, Germany | Recruiting |
| Medizinische Hochschule Hannover | Hannover, Germany | Not Yet Recruiting |
| Medizinische Hochschule Hannover (MHH) | Hanover, Germany | Not Yet Recruiting |
| UCT University Medical Center Mainz | Mainz, Germany | Not Yet Recruiting |
| Hospital Universitario Reina Sofia | Córdoba, Spain | Recruiting |
| Gregorio Marañón General University Hospital | Madrid, Spain | Recruiting |
| Hospital Universitario La Paz | Madrid, Spain | Not Yet Recruiting |
| Hospital Universitario Virgen del Rocio | Seville, Spain | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07549698